This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Princeton University. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Mohamed Abou Donia: Inventor in Microbiome-Based Drug Metabolism
Introduction
Mohamed Abou Donia is an inventor associated with Princeton, New Jersey, and Princeton University. His work includes a patented quantitative screening approach for studying how the human gut microbiome affects drug metabolism and individual responses to medication.
Latest Patents
Abou Donia is listed with 1 patent: “Quantitative Screen for the Assessment of Inter-Individual Variability in Drug Metabolism by the Human Gut Microbiome.” The invention describes MDMQ-Screen, a method for measuring and explaining differences in microbiome-derived drug metabolism among individuals. This information may help researchers investigate unexplained variation in drug response and toxicity, inform clinical-trial design and interpretation, and support personalized therapeutic recommendations.
Career Highlights
The patent focuses on the relationship between the gut microbiome and the way medications are metabolized. By assessing this relationship, MDMQ-Screen is intended to help evaluate potential toxic effects and differences in treatment response.
Collaborations
Abou Donia is associated with Princeton University. His listed coworkers include Bahar Javdan and Jaime Lopez.
Conclusion
Mohamed Abou Donia’s patent presents a quantitative approach to understanding how gut microbiome differences may influence drug metabolism, treatment response, and medication safety.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile